CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma

被引：0

作者：

Zi, Dan ^{[1
,2
,3
,4
,5
,6
]}

Li, Qing ^{[7
,8
,10
]}

Xu, Cheng-xiong ^{[7
,8
,10
]}

Zhou, Zhi-Wei ^{[9
]}

Song, Guan-Bin ^{[9
]}

Hu, Cheng-Bin ^{[11
]}

Wen, Fang ^{[2
]}

Yang, Han-Lin ^{[2
]}

Nie, Lei ^{[2
]}

Zhao, Xing ^{[3
]}

Tan, Jun ^{[4
,5
]}

Zhou, Shu-Feng ^{[6
,12
]}

He, Zhi-Xu ^{[3
,13
]}

机构：

[1] Guizhou Prov Peoples Hosp, Dept Obstet & Gynecol, Guiyang 550002, Guizhou, Peoples R China

[2] Guizhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp, Guiyang 550004, Peoples R China

[3] Guizhou Med Univ, Guizhou Med Univ, Key Lab Adult Stem Cell Transformat Res, Stem Cell & Tissue Engn Res Ctr, Guiyang 550004, Peoples R China

[4] Guizhou Med Univ, Key Lab Endem & Ethn Dis, Minist Educ, Key Lab Mol Biol, Guiyang 550004, Peoples R China

[5] Guizhou Med Univ, Key Lab Mol Biol, Minist Educ, Guiyang 550004, Peoples R China

[6] Univ S Florida, Dept Pharmaceut Sci, Coll Pharm, Tampa, FL 33612 USA

[7] Third Mil Med Univ, Daping Hosp, Ctr Canc, Chongqing 40042, Peoples R China

[8] Third Mil Med Univ, Res Inst Surg, Ctr Canc, Chongqing 40042, Peoples R China

[9] Univ Texas SouthWestern Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA

[10] Chongqing Univ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400030, Peoples R China

[11] Univ S Florida, Dept Comp Sci & Engn, Tampa, FL 33620 USA

[12] Huaqiao Univ, Coll Chem Engn, Dept Bioengn & Biotechnol, Xiamen 361021, Fujian, Peoples R China

[13] Zunyi Med Univ, Dept Pediat, Affiliated Hosp, Zunyi 563000, Guizhou, Peoples R China

来源：

AGING-US | 2022年 / 14卷 / 11期

基金：

中国国家自然科学基金;

关键词：

CXCR4; PI3K/Akt/mTOR; CSCs; ovarian cancer; PTX; EPITHELIAL-MESENCHYMAL TRANSITION; CELL INVASION; CANCER; METASTASIS; OVEREXPRESSION; ACTIVATION; RECEPTORS; PROMOTES; LUNG; AXIS;

D O I：

暂无

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy. EOC control remains difficult, and EOC patients show poor prognosis regarding metastasis and chemotherapy resistance. The aim of this study was to estimate the effect of CXCR4 knockdown-mediated reduction of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) stemness and enhancement of chemotherapy sensitivity in EOC. Mechanisms contributing to these effects were also explored. Our data showed distinct contribution of CXCR4 overexpression by dependent PI3K/Akt/mTOR signaling pathway in EOC development. CXCR4 knockdown resulted in a reduction in CSCs and EMT formation and enhancement of chemotherapy sensitivity in tumor cells, which was further advanced by blocking CXCR4-PI3K/Akt/mTOR signaling. This study also documented the critical role of silencing CXCR4 in sensitizing ovarian CSCs to chemotherapy. Thus, targeting CXCR4 to suppress EOC progression, specifically in combination with paclitaxel (PTX) treatment, may have clinical application value.

引用

页码：4673 / 4698

页数：26

共 50 条

[41] HER4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway
Li, Xiaodong
Huang, Qingshan
Wang, Shenglin
Huang, Zhen
Yu, Fengqiang
Lin, Jianhua
ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2020, 52 (04) : 354 - 362
[42] Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck
Simpson, Daniel R.
Mell, Loren K.
Cohen, Ezra E. W.
ORAL ONCOLOGY, 2015, 51 (04) : 291 - 298
[43] Sodium Propionate Attenuates the Lipopolysaccharide-Induced Epithelial-Mesenchymal Transition via the PI3K/Akt/mTOR Signaling Pathway
Chen, Dan
Qiu, Yu-bao
Gao, Zhi-qi
Wu, Ya-xian
Wan, Bin-bin
Liu, Gang
Chen, Jun-liang
Zhou, Qin
Yu, Renqiang
Pang, Qingfeng
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2020, 68 (24) : 6554 - 6563
[44] The role of PI3K/AKT signaling pathway in gallbladder carcinoma
Wu, Zeyu
Yu, Xiao
Zhang, Shuijun
He, Yuting
Guo, Wenzhi
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (07): : 4426 - 4442
[45] The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
Fulda, S.
CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 729 - 737
[46] Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Markman, Ben
Dienstmann, Rodrigo
Tabernero, Josep
ONCOTARGET, 2010, 1 (07) : 530 - 543
[47] Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway
Wang, Haiyong
Zhang, Chenyue
Xu, Litao
Zang, Kun
Ning, Zhouyu
Jiang, Feng
Chi, Huiying
Zhu, Xiaoyan
Meng, Zhiqiang
ONCOTARGET, 2016, 7 (15) : 20193 - 20208
[48] CXCR4 was involved in andrographolide inhibits atherosclerosis by inactivating the PI3K/AKT/NF-κB signaling pathway
Xie, Lijuan
Chen, Zhuo
Yang, Songbai
Wang, Zhanpeng
Hou, Xuhui
Yin, Jian
Li, Wei
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (04): : 4191 - 4197
[49] TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway
Li, Liyin
Qi, Yanhua
Ma, Xiaobo
Xiong, Guosheng
Wang, Lijun
Bao, Cuixia
CELL BIOLOGY INTERNATIONAL, 2018, 42 (09) : 1192 - 1199
[50] Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
Chen, Dongshao
Lin, Xiaoting
Zhang, Cheng
Liu, Zhentao
Chen, Zuhua
Li, Zhongwu
Wang, Jingyuan
Li, Beifang
Hu, Yanting
Dong, Bin
Shen, Lin
Ji, Jiafu
Gao, Jing
Zhang, Xiaotian
CELL DEATH & DISEASE, 2018, 9

← 1 2 3 4 5 →